Results of MERCI trial paves the path for thrombolysis after 6 hours window...
- An interesting article
- All this time we have been following the dictum 'time is brain' although in practice a lot of patients have been benefited by thrombolysis after 6 hours. No the MERCI collaboratos have come out with with data to prove the same. A big thumbs up for them...It not only ahall pave the path for more patient oriented work, but also alter our thinking of the pathophysiology of stroke and the path our research should take.
-
- Original Contributions
Effect of Time to Reperfusion on Clinical Outcome of Anterior Circulation Strokes Treated With Thrombectomy
Pooled Analysis of the MERCI and Multi MERCI Trials
- Raul G. Nogueira, MD;
- Wade S. Smith, MD, PhD;
- Gene Sung, MD;
- Gary Duckwiler, MD;
- Gary Walker, PhD;
- Robin Roberts, BSc, MSc;
- Jeffrey L. Saver, MD;
- David S. Liebeskind, MD
- on Behalf of the MERCIMulti MERCI Writing Committee
+Author Affiliations
- From the Departments of Neurology, Neurosurgery, and Radiology (R.G.N.),
- Emory University School of Medicine, Marcus Stroke & Neuroscience Center,
- Grady Memorial Hospital, Atlanta, GA; Department of Neurology (W.S.S.), University of California,
- San Francisco, CA; Department of Neurology (G.S.), University of Southern California, Los Angeles,
- CA; Department of Interventional Neuroradiology (G.D.), University of California, Los Angeles,
- CA; Division of Clinical Research (G.W.), Concentric Medical Inc, Mountain View, CA;
- Department of Clinical Epidemiology & Biostatistics (R.R.), McMaster University, Hamilton,
- ON, Canada; Department of Neurology (J.L.S., D.S.L.), University of California, Los Angeles, CA.
- Correspondence to Raul G. Nogueira, MD, Emory Faculty Office Building 80 Jesse Hill Dr. SE, Room 398, Atlanta, GA 30303. E-mail rnoguei@emory.edu
Abstract
Background and Purpose—Previous studies have demonstrated a strong correlation between treatment time and outcomes after intravenous recombinant tissue-type plasminogen activator. However, the temporal profile of ischemia may vary according to the level of occlusion, and it is likely that more proximal occlusions have a more variable temporal course than their distal counterparts. We sought to establish how time influences outcomes in anterior circulation proximal arterial occlusions.
Methods—All patients from the MERCI/Multi MERCI trials with intracranial internal carotid artery and/or middle cerebral artery (M1-M2 segments) occlusions who were successfully revascularized were included in univariate/multivariate analyses to define the predictors of independent functional outcomes (modified Rankin Scale score ≤2) and mortality at 90 days. The effect of time to reperfusion on outcomes was calculated after adjustment for age, baseline National Institutes of Health Stroke Scale, and glucose levels.
Results—A total of 175 patients presenting with internal carotid artery/M1/M2 occlusions were revascularized. There was no definite association between time (to treatment or reperfusion) and outcomes in the unadjusted analysis. Baseline National Institutes of Health Stroke Scale score and age were independent predictors of independent outcome and mortality. High glucose demonstrated a strong trend toward worse outcomes. After adjustment for age, baseline National Institutes of Health Stroke Scale score, and glucose, there was a strong trend toward fewer independent outcomes with later reperfusion times. Notably, 40% of the patients reperfused at ≥6.9 hours achieved independent functional outcomes.
Conclusions—Time (to treatment or reperfusion) is only one of the many variables that may impact outcome in proximal arterial occlusions strokes. Reperfusion therapies should be started promptly, but our findings also suggest that stroke patients presenting at later time points may still benefit.
Key Words:
Curative embolization of brain arteriovenous malformations (AVM): Because We Could or Because We Should?
Brain AVMs for long had been enigmatic and 'touch me not' lesions, that is until some expert super confident vascular neurosurgeons started operating upon them, and some of them did pretty good job too. Also, radiosurgery ( gamma knife) has excellent results in a large number of these rather badly understood lesions. However, with the advent of smart endovascular neurointerventionists, they also started being treated by embolisation, initially as an adjunct to surgery of radiosurgery, and of late has been propagated as a single modality complete cure, especially with the advent and spread of ONYX.
However, the great interventional neuroradiologists advice a word of caution in following this approah.
Follow this link to see a good commentary by Jayaraman and Cloft.
http://www.ajnr.org/cgi/content/full/30/1/107
And here is an excellent reply to the above one from katsaridis
http://www.ajnr.org/cgi/content/full/30/5/e67
And here is an excellent comment in AJNR blog by the revered teacher Pearse Morris regarding the same point as Jayaraman.
This comment has incited a fantastic discussion on the above blog page among some of the biggest names in neurointervention.
http://www.ajnrblog.org/2009/02/02/embolization-of-brain-arteriovenous-malformations-for-cure/
And here is the link to the original article which started it all: the one by Panagiotopoulos et al
http://www.ajnr.org/cgi/content/short/ajnr.A1314v1
Mechanical Thrombectomy using SOLITAIRE FR stent system
For thrombectomy, the stent has to be inserted and used in the regular way. But after waiting for few minnuted for flow restoration to occur, the stent and the delivery microcatheter are pulled out from the guide catheter. The clot get entangled in the wall of the stent and comes out along with it. Multiple repeated passes of the stent may be needed before obtaining a satisfactoy result. Thus in practice it works like any other thrombectomy device.
Below is a case demonstration of the same.
Watch an animation of the Solitaire FR system
Below is a screenshot of the eV3 Solitaire FR information webpage
Patient Resources: Embolisation
Embolism refers to the migration of any substance not native to the blodd vessel coming from some other source.e.g tumor embolism wherein fragments of tumor invade the blodd vessel and carry on with the blood flow to occlude some other vessel. The process is called embolism, the material transported is called embolus (plural: emboli)
Embolization is a non-surgical, minimally-invasive procedure performed by an interventional radiologist and interventional neuroradiologists. It involves the selective occlusion of blood vessels by purposely introducing embolic material into the target blodd vessel.
The medical dictionary definition of embolisation is "therapeutic introduction of various substances into the circulation to occlude vessels, either to arrest or prevent hemorrhaging; to devitalize a structure, tumor, or organ by occluding its blood supply; or to reduce blood flow to an arteriovenous malformation."
Usage
Embolisation is used to treat a wide variety of conditions affecting different organs of the human body.
- Arteriovenous malformations (AVMs) and other vascular malformations
- Aneurysm
- Gastrointestinal bleeding
- Epistaxis
- Primary post-partum hemorrhage
- Surgical hemorrhage
- Post traumatic hemorrhage
- uterine fibroids
- Kidney lesions
- Liver lesions, typically hepatocellular carcinoma (HCC). Treated either by particle infarction or transcatheter arterial chemoembolization (TACE).
- Portal venous hypertension
- An adjunctive goal (eg, preoperative, adjunct to chemotherapy or radiation therapy)
- A curative goal (eg, definitive treatment such as that performed in cases of aneurysms, arteriovenous fistulae [AVFs], arteriovenous malformations [AVMs], and traumatic bleeding)
- A palliative goal (eg, relieving symptoms, such as those of a large AVM, which cannot be cured by using embolotherapy alone)
Embolization Materials And Substances
Coils
Click here to see an example of coil embolisation (coiling) of an intracranial aneurysm
Ethanol
Sodium tetradecyl sulfate
Cyanoacrylate
Polyvinyl alcohol
Tris-acryl gelatin microspheres
Gelfoam
Click here to see an example of balloon embolisation of a carotico-cavernous fistula (CCF)
Other materials
ONYX is a patented liquid embolic material from ev3 company, a relatively new entrant in the field of interventional neuroradiology and has provided an exciting new way treat complex AVMs and dural AVFs which otherwise were difficult to treat.
Onyx® LES
- Onyx is comprised of EVOH (ethylene vinyl alcohol) copolymer dissolved in DMSO (dimethyl sulfoxide), and suspended micronized tantalum powder to provide contrast for visualization under fluoroscopy.
- The Onyx Liquid Embolic System (LES) consists of a 1.5 ml vial of Onyx, a 1.5 ml vial of DMSO, and three 1 ml Onyx delivery syringes.
- A DMSO compatible delivery micro catheter that is indicated for use in the neuro vasculature (e.g. Marathon™, Rebar® or UltraFlow™ HPC catheters) is used to access the embolization site.
- Onyx is available in two product formulations, Onyx 18 (6% EVOH) and Onyx 34 (8% EVOH).
Onyx® HD-500
Onyx® 500 is a non-adhesive liquid embolic agent used for the embolization of brain aneurysms.- Onyx HD500 is comprised of 20% EVOH (ethylene vinyl alcohol) copolymer dissolved in DMSO (dimethyl sulfoxide), and suspended micronized tantalum powder to provide contrast for visualization under fluoroscopy.
- Onyx HD500 (20% EVOH) is an HDE device for the treatment of intracranial, saccular, sidewall aneurysms that present with a wide neck (≥ 4mm) or with a dome-to-neck ratio < 2 that are not amenable to treatment with surgical clipping.
- Onyx HD500 can also be used in adjunctive therapy with Axium coils and stents.
Procedure
Advantages
- Minimally invasive
- No scarring
- Minimal risk of infection
- No or rare use of general anesthetic
- Faster recovery time
- High success rate compared to other procedures
- Preserves fertility and anatomical integrity
Disadvantages
- User dependent success rate
- Risk of emboli reaching healthy tissue
- Not suitable for everyone
- Recurrence more likely





